These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1815518)

  • 1. Effects of the new cardiotonic phosphodiesterase inhibitor 1,2-dihydro-5- imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridine-carbonitrile hydrochloride monohydrate on aortic input impedance.
    Kubota T; Itaya R; Todaka K; Sugimachi M; Sunagawa K; Takeshita A
    Arzneimittelforschung; 1991 Dec; 41(12):1211-5. PubMed ID: 1815518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
    Ohhara H; Ogawa T; Takeda M; Katoh H; Daiku Y; Igarashi T
    Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.
    Ogawa T; Ohhara H; Tsunoda H; Kuroki J; Shoji T
    Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of extraanatomic bypass on aortic input impedance studied in open chest dogs. Should the vascular prosthesis be compliant to unload the left ventricle?
    Morita S; Kuboyama I; Asou T; Tokunaga K; Nose Y; Nakamura M; Harasawa Y; Sunagawa K
    J Thorac Cardiovasc Surg; 1991 Nov; 102(5):774-83. PubMed ID: 1834892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,2-a]pyridines. I. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives.
    Yamanaka M; Miyake K; Suda S; Ohhara H; Ogawa T
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1556-67. PubMed ID: 1934178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral and cardiac effects of a new phosphodiesterase inhibitor in comparison with enoximone.
    Schröder T; Hering JP; Foth H; Ferrari M; Sipinková I; Hellige G
    Arzneimittelforschung; 1994 Aug; 44(8):948-50. PubMed ID: 7945538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac and hemodynamic effects of intravenous R 80122, a new phosphodiesterase III inhibitor, in anesthetized and awake dogs.
    Van de Water A; d'Aubioul J; Van Gerven W; de Chaffoy de Courcelles D; Freyne E; Xhonneux R; Reneman RS; Janssen PA
    Arch Int Pharmacodyn Ther; 1992; 316():60-74. PubMed ID: 1530374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
    Tanio H; Kumada T; Hayashi M; Himura Y; Nakamura Y; Kawai C
    Jpn Circ J; 1991 Nov; 55(11):1068-76. PubMed ID: 1749068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-[imidazo (1,2-a) pyridin-6-yl]-3-pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP metabolism in canine ventricular muscle.
    Satoh H; Endoh M
    Jpn J Pharmacol; 1990 Feb; 52(2):215-24. PubMed ID: 2156096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of AR-L 115 BS on myocardial oxygen consumption, cardiac performance and vascular resistance and capacitance.
    Dämmgen J; Kadatz R; Diederen W
    Arzneimittelforschung; 1981; 31(1a):151-4. PubMed ID: 7195209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.
    Tomoyasu M; Onizuka M; Inagaki M; Sato Y; Yamamoto T; Ishikawa S; Mitsui T
    Lymphology; 2002 Dec; 35(4):144-52. PubMed ID: 12570323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart.
    Takaoka H; Takeuchi M; Odake M; Hayashi Y; Mori M; Hata K; Yokoyama M
    J Am Coll Cardiol; 1993 Aug; 22(2):598-606. PubMed ID: 8335835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propofol alters left ventricular afterload as evaluated by aortic input impedance in dogs.
    Lowe D; Hettrick DA; Pagel PS; Warltier DC
    Anesthesiology; 1996 Feb; 84(2):368-76. PubMed ID: 8602668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial artery.
    Adachi H; Kamata S; Kodama K; Nagakura T
    Eur J Pharmacol; 2000 May; 396(1):43-7. PubMed ID: 10822053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation.
    Tanoue Y; Morita S; Nagano I; Ochiai Y; Tominaga R; Kawachi Y; Yasui H
    Jpn J Thorac Cardiovasc Surg; 2001 Oct; 49(10):607-13. PubMed ID: 11692586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute clinical benefits of a new inotropic agent AR-L 115 BS after i.v. and oral administration.
    el Allaf D; D'Orio V; Cremers S; Carlier J
    G Ital Cardiol; 1984 Oct; 14(10):830-4. PubMed ID: 6519393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
    Adachi H; Tanaka H
    J Cardiovasc Pharmacol; 1997 Jun; 29(6):763-71. PubMed ID: 9234657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.